Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences (NYSE: EW) has announced it will release its Q4 2024 operating results after market close on February 11, 2025. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893.

The call will be available live and archived in the Investor Relations section of Edwards' website at ir.edwards.com. Edwards Lifesciences is positioned as the global leader in structural heart innovation, focusing on developing breakthrough technologies and maintaining partnerships with healthcare stakeholders.

Edwards Lifesciences (NYSE: EW), the global leader in structural heart innovation, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Bernard Zovighian, CEO, will present at 11:15 a.m. PT, accompanied by CFO Scott Ullem.

The presentation will be accessible through a live webcast on the company's investor relations website at http://ir.edwards.com/, with an archived version available later the same day. Edwards Lifesciences focuses on developing breakthrough technologies and maintaining partnerships with healthcare stakeholders to deliver life-changing innovations to patients in need.

Edwards Lifesciences (NYSE: EW) outlined its 2025 growth strategy and financial guidance at its annual investor conference. The company reaffirmed its 2024 constant currency sales growth guidance of 8-10% and projected similar growth for 2025 with adjusted EPS of $2.40-$2.50.

Key financial projections for 2025 include TAVR sales of $4.1-$4.4 billion (5-7% growth) and TMTT sales of $500-$530 million (50-60% growth). The company targets 10% average annual total company sales growth and double-digit EPS growth beyond 2026, with TMTT expected to reach $2 billion by 2030.

Growth drivers include EARLY TAVR indication approval, PASCAL, EVOQUE, and SAPIEN M3 therapies, along with expansion into Structural Heart Failure and Aortic Regurgitation treatments.

Edwards Lifesciences (NYSE: EW) announced one-year data showing exceptional performance of its SAPIEN 3 Ultra RESILIA valve. Analysis of over 9,000 propensity-matched patients revealed superior outcomes compared to earlier valve generations, with extremely low mortality, low reintervention rates, and no paravalvular leak in 84.4% of cases. Patients experienced significant quality of life improvements with an average 31-point increase in KCCQ score and brief one-day hospital stays, with 93% discharged home. The study population had an average STS score of 3.6 and average age of 77.

Edwards Lifesciences (NYSE: EW) presented new clinical data at the Transcatheter Cardiovascular Therapeutics (TCT) conference, emphasizing its commitment to structural heart innovation. The data from the EARLY TAVR and TRISCEND II trials highlighted the importance of early intervention in severe aortic stenosis and the benefits of transcatheter mitral and tricuspid therapies (TMTT). Key findings included improved outcomes and reduced healthcare costs for patients receiving timely treatment. Specific studies showcased the efficacy of TAVR in asymptomatic severe aortic stenosis patients and women, and the long-term benefits of the PASCAL system in treating mitral regurgitation. Additionally, the TWIST study demonstrated promising results for Innovalve in mitral valve replacement. These findings support Edwards' growth and innovation in treating structural heart disease.

Edwards Lifesciences (NYSE: EW) announced superior one-year results for its EVOQUE transcatheter tricuspid valve replacement system in the TRISCEND II trial. The study, involving 400 patients with severe tricuspid regurgitation, showed 95.4% successful implantation rate. 95.3% of treated patients achieved near-complete tricuspid regurgitation elimination at one year, compared to just 2.3% in the control group receiving optimal medical therapy alone. The EVOQUE system, now approved in both Europe and US, demonstrated significant improvements in symptoms, function, and quality of life, with favorable trends in mortality and heart failure hospitalization.

Edwards Lifesciences (NYSE: EW) announced groundbreaking results from the EARLY TAVR Trial, demonstrating superior outcomes for asymptomatic severe aortic stenosis patients treated with TAVR compared to clinical surveillance. The trial, involving 901 patients across 75 sites in the US and Canada, showed that 26.8% of TAVR patients experienced death, stroke, or unplanned cardiovascular hospitalization versus 45.3% in the surveillance group over a 3.8-year median follow-up. Early TAVR intervention prevented rapid symptom progression and quality of life decline, with lower stroke rates (4.2% vs 6.7%). Notably, 26.2% of surveillance patients required valve replacement within six months, rising to 47.2% at 12 months.

Edwards Lifesciences (NYSE: EW) reported Q3 2024 financial results with total sales growth of 9% (10% constant currency) from continuing operations. TAVR sales reached $1.0 billion, growing 6%, while TMTT sales showed significant growth of 73%. The company reported Q3 EPS of $5.13 and adjusted EPS of $0.67. The quarter was marked by the completion of Critical Care divestiture and continued progress in PASCAL and EVOQUE commercial launches. Edwards maintained its full-year 2024 sales guidance ranges and expects Q4 sales between $1.33-$1.39 billion with EPS of $0.53-$0.57.

Edwards Lifesciences (NYSE: EW) has announced plans to release its Q3 2024 operating results on October 24, 2024, after market close. The company will host a conference call at 5:30 p.m. ET to discuss the results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the company's investor relations website.

Edwards Lifesciences is a global leader in patient-focused innovations for structural heart disease. The company is committed to improving lives through partnerships with clinicians and healthcare stakeholders worldwide.